Vidarbha News

Neurofibromatosis Market Trends and Growth Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Neurofibromatosis Market Trends and Growth Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

May 18
04:26 2021
Neurofibromatosis Market Trends and Growth Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Neurofibromatosis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Neurofibromatosis (NF) is a rare genetic disorder that causes typically benign tumors of the nerves and growth in other parts of the body. Some people with this disorder have barely noticeable neurological problems, while others are affected profoundly. NF has been classified into three distinct types; NF1, NF2, and schwannomatosis. They are caused by different genes, located on different chromosomes.

NF1 is caused by mutations in the gene that controls the production of a protein called neurofibromin (neurofibromin 1). This gene is believed to function as a tumor suppressor. NF2 results from mutations in a different tumor-suppressing gene (neurofibromin 2, merlin). Although most cases of NF1 are mild to moderate, NF1 can lead to disfigurement; blindness; skeletal abnormalities; dermal, brain, and spinal tumors; loss of limbs; malignancies; and learning disabilities.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/neurofibromatosis-market

Neurofibromatosis Market

The Neurofibromatosis market report also covers emerging drugs, current treatment practices, Neurofibromatosis market share of the individual therapies, current and forecasted Neurofibromatosis Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Neurofibromatosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Neurofibromatosis Market Key Facts

  • According to the National Institute of Neurological Disorder and Stroke, NF1 is the most common neurofibromatosis, occurring in 1 in 3,000 to 4,000 individuals in the United States. Although many affected people inherit the disorder, between 30 and 50 percent of new cases result from a spontaneous genetic mutation of an unknown cause. Once this mutation has taken place, the mutant gene can be passed to succeeding generations.

  • According to the Neurofibromatosis Clinics Association, NF1 is the most common neurological disorder caused by a single gene; occurring in one in every 3,000 children born NF2 is a rarer type, occurring in 1:25,000 people worldwide. schwannomatosis occurs in 1:40,000 people.

  • According to the American Association of Neurological Surgeons: There is a 50-percent chance that each child of a parent with NF1 or NF2 will inherit the gene and develop NF1 or NF2 (respectively) this is known as autosomal dominant inheritance pattern.

Key Benefits of Neurofibromatosis Market Report

  • Neurofibromatosis market report provides an in-depth analysis of Neurofibromatosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Neurofibromatosis market report will help in developing business strategies by understanding the Neurofibromatosis Market trends & developments, key players, and future market competition that will shape and drive the Neurofibromatosis market in the upcoming years.

  • The Neurofibromatosis market report covers Neurofibromatosis’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Neurofibromatosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Neurofibromatosis Market

Neurofibromatosis market size is expected to increase during the forecast period owing to the extensive research and development activities of pharmaceutical companies to develop the therapies for Neurofibromatosis.

The Neurofibromatosis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Neurofibromatosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Neurofibromatosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Neurofibromatosis Epidemiology

The Neurofibromatosis epidemiology section covers insights about the historical and current Neurofibromatosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Neurofibromatosis Epidemiology Subtype Segmentation

  • Prevalent Population of Neurofibromatosis

  • Type-Specific Prevalent Population of Neurofibromatosis

  • Diagnosed & Treatable Cases of Neurofibromatosis

Neurofibromatosis Drugs Uptake and Key Market Players

The Neurofibromatosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched in the market during the study period. The analysis covers Neurofibromatosis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

At present, no effective medical therapies are known for neurofibromatosis and treatment does not assure complete cure and involves constant medication throughout the therapeutic course. There are certain shortcomings associated with complete surgical resection.

The dynamic of the Neurofibromatosis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period. Companies across the globe are diligently working towards the development of new treatment therapies for Neurofibromatosis.

Neurofibromatosis Companies:
AstraZeneca
Array Biopharma
Novartis
SpringWorks Therapeutics
And many others.

Neurofibromatosis therapies covered in the report include:
Selumetinib
Binimetinib
PD-0325901
Trametinib
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Neurofibromatosis Competitive Intelligence Analysis

4. Neurofibromatosis Market Overview at a Glance

5. Neurofibromatosis Disease Background and Overview

6. Neurofibromatosis Patient Journey

7. Neurofibromatosis Epidemiology and Patient Population

8. Neurofibromatosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Neurofibromatosis Unmet Needs

10. Key Endpoints of Neurofibromatosis Treatment

11. Neurofibromatosis Marketed Products

12. Neurofibromatosis Emerging Therapies

13. Neurofibromatosis Seven Major Market Analysis

14. Attribute Analysis

15. Neurofibromatosis Market Outlook (7 major markets)

16. Neurofibromatosis Access and Reimbursement Overview

17. KOL Views on the Neurofibromatosis Market.

18. Neurofibromatosis Market Drivers

19. Neurofibromatosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/neurofibromatosis-market

Latest Reports By DelveInsight –
Neurofibromatosis Pipeline Insights
Neurofibromatosis Pipeline Insight 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis market.

Endometrial Cancer Market
DelveInsight’ s “Endometrial Cancer Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Endometrial Cancer market size, share, trends, growth, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/